What happened with BMRN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
BioMarin Pharmaceuticals serves patients with rare, genetically defined conditions, many of whom need long-term treatment. Enzyme therapies account for most of its product revenue, led by VIMIZIM and NAGLAZYME. Its largest individual product is VOXZOGO, which treats achondroplasia, a condition affecting bone growth.
The company sells medicines to specialty pharmacies, hospitals, government purchasers and distributors. A small group of customers accounts for a substantial share of sales. ALDURAZYME follows a separate arrangement: BioMarin manufactures and supplies it to Sanofi, its sole customer for that medicine. Sanofi holds exclusive worldwide marketing and sales rights and pays BioMarin a share of its net sales.
Insurance and government reimbursement are essential because most families cannot afford these treatments directly. The business depends on finding patients, keeping them on therapy and securing coverage at prices that support the medicines’ development and manufacture. In many countries, commercial launches must wait for pricing or reimbursement approval.
Some products also face specific access conditions. In the United States, PALYNZIQ can be prescribed and dispensed only through an FDA-required safety program involving certified prescribers and pharmacies and enrolled patients. VOXZOGO’s continued U.S. approval may depend on confirmatory studies verifying its clinical benefit.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
BioMarin’s results hinge on VOXZOGO growth and sustained enzyme-therapy sales, while its announced acquisition of Amicus Therapeutics would add Fabry and Pompe treatments and substantially reshape its portfolio.
Ascendis Pharma’s TransCon CNP could compete for children with achondroplasia treated by BioMarin’s VOXZOGO, its largest revenue-generating medicine. Watch its US and EU approval reviews and patent disputes with BioMarin: these affect when that competition can enter the market.
PTC Therapeutics already competes for the PKU patients served by BioMarin’s PALYNZIQ and KUVAN through its oral medicine Sephience. Sephience sales are the part of PTC’s rare-disease business to watch for competition facing those two BioMarin medicines.
BridgeBio Pharma’s oral infigratinib could compete with BioMarin’s largest-selling medicine, VOXZOGO, for achondroplasia patients if approved. For BioMarin holders, its late-stage development matters more directly than BridgeBio’s current sales of Attruby for adults with transthyretin amyloid cardiomyopathy.
Sanofi exclusively buys BioMarin-made ALDURAZYME for MPS I and sells it worldwide, paying BioMarin 39.5%–50% of worldwide net sales depending on volume. Watch ALDURAZYME sales and order-fulfillment timing: deliveries to Sanofi helped lift BioMarin’s revenue from the medicine in 2025.
Tyra Biosciences is developing oral dabogratinib for achondroplasia, potentially competing with BioMarin’s VOXZOGO and its medicines in development for skeletal conditions. Watch progress in the skeletal-disease program, which targets FGFR signaling, rather than Tyra’s cancer programs.
REGENXBIO’s RGX-111 could eventually compete with BioMarin’s ALDURAZYME for MPS I patients, while RGX-202 overlaps BioMarin’s Duchenne drug-development program. RGX-111’s development with Nippon Shinyaku is the program to watch for potential competition to BioMarin’s existing medicine sales.
BioMarin Pharmaceuticals Inc earningsThis company
BioMarin’s product revenue depends on new-patient demand, the timing of large government orders and generic competition, and this report will show whether VOXZOGO-led growth can hold.
Read VOXZOGO and enzyme-therapy product revenue alongside gross margin. Growth across both groups with margin holding would show patient demand is offsetting government-order timing swings and generic pressure on KUVAN. If growth relies on large orders being recorded while VOXZOGO weakens or margin falls, revenue concentration and costs still leave growth vulnerable.
PTC Therapeutics, Inc. earningsPTCT
PTC Therapeutics’ report will show demand for its oral medicine Sephience among PKU patients, a market where it competes with BioMarin’s PALYNZIQ and KUVAN.
Watch Sephience sales. Stronger sales would suggest that more people with PKU may be choosing a medicine that competes with PALYNZIQ and KUVAN, increasing competitive pressure on BioMarin’s PKU products. Weaker sales would indicate less demand pull from this competitor, but would not prove BioMarin is gaining patients.
Sanofi earningsSNY
Sanofi exclusively sells BioMarin-made ALDURAZYME worldwide, so its sales affect BioMarin’s volume-based share, while delivery timing affects when BioMarin records product revenue.
Compare Sanofi’s reported worldwide ALDURAZYME sales with BioMarin’s revenue from the medicine and its order deliveries. Higher Sanofi sales mean a larger sales base for BioMarin’s share; if BioMarin’s revenue does not rise alongside them, delivery timing may explain the gap. Weaker sales mean a smaller base for that share, and delayed deliveries can push BioMarin’s recorded revenue later. The two companies’ figures need not move in the same period.
REGENXBIO Inc. earningsRGNX
REGENXBIO’s report will show RGX-111’s development progress; if the MPS I therapy advances, it could eventually compete with BioMarin’s ALDURAZYME.
Watch the RGX-111 program with Nippon Shinyaku and any new development milestones. Clear progress would bring this potential MPS I competitor closer to the market and could affect BioMarin’s existing ALDURAZYME business; a stalled or delayed program would leave competition further off. Progress alone would not mean RGX-111 is approved or taking patients.
Ascendis Pharma A/S earningsASND
Ascendis Pharma’s report will show how its TransCon CNP reviews and patent disputes are progressing, factors that affect when it could compete with BioMarin’s VOXZOGO for children with achondroplasia.
Read the U.S. and EU review updates together with the patent disputes. Progress toward approval and a clearer path through the disputes would bring TransCon CNP closer to market and potential competition with VOXZOGO; delays or obstacles to entry would push that competition further away. Review progress does not mean patients have switched to the medicine.
